Figure 2.

CMCS treatment promotes activation of hepatic NK cells in mice with CCl₄-induced liver fibrosis. (A) Liver lymphocytes were analyzed by FACS with APC-conjugated rat anti-mouse NK1.1 antibody and PE-Cy7-conjugated rat anti-mouse monoclonal antibody. (B) For NKG2D identification, a PE-conjugated rat anti-mouse NKG2D antibody was used. The expression of NKG2D from A was analyzed by FACS. (C) Numbers of NK1.1⁺CD3⁻ cells in liver lymphocytes were counted. (D) Expression of NKG2D in NK1.1⁺CD3⁻ cells was quantified. (E & F) mRNA levels of RAE-1δ and RAE-1ε in liver samples were analyzed by RT-qPCR. Values represent mean±SD (n=10). ^bP<0.05, ^cP<0.01, versus normal control group; ^eP<0.05, ^fP<0.01, versus model control group.